A phase II, randomized, open-label study to assess the efficacy of extended-dose schedule administration of darbepoetin alfa in cancer patients with chemotherapy-induced anemia

Journal of Supportive Oncology

Volumn 5, Issue 4 SUPPL. 2, 2007, Pages 22-23

  Schwartzberg, Lee ^a   Rearden, Timothy ^a   Yee, Lorrin ^a   Mirtsching, Barry ^a   Charu, Veena ^a   Lam, Hung ^a   Lillie, Tom ^a   Burkes, Ronald ^a   Silberstein, Peter ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN;

ADULT; ANEMIA; CANADA; CANCER; CANCER PATIENT; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TOLERABILITY; ERYTHROCYTE TRANSFUSION; FATIGUE; FUNCTIONAL ASSESSMENT; GYNECOLOGIC CANCER; HEMOGLOBIN BLOOD LEVEL; HUMAN; KAPLAN MEIER METHOD; LUNG CANCER; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OPEN STUDY; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; THROMBOEMBOLISM; UNITED STATES;

EID: 34250615108     PISSN: 15446794     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (1)

1. Schwartzberg L, Rearden T,Yee L, et al. A phase II, randomized, open-label study to assess the efficacy of extended-dose schedule administration of darbepoetin alfa in cancer patients with chemotherapy-induced anemia. Presented at the 48th Annual Meeting of the American Society of Hematology; December 9-12, 2006; Orlando, Florida.Abstract 1306.